Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Gray Areas: Do Sleep Disorders Actually Drive Neurodegenerative Disease?
2
Defining Precision Medicine in Multiple Sclerosis
3
Shared Decision-Making for Agitation in Specialty Care and Disease Trajectory
4
NeurologyLive® Friday 5 — October 9, 2026
5